You are here: Industry Insights > Investment

News List

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.
MSD, BI and CStone Pharmaceuticals Made Significant Investments in ROR1 ADC Far-away from the Crowd
May 06, 2024
Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.
Under the new policy tilt, how can MNCs increase their investment in China? Yefenghong/PharmaSources
September 08, 2023
On August 13th, the State Council issued the "Opinions on Further Optimizing the Foreign Investment Environment and Increasing the Attractiveness of Foreign Investment" (hereinafter referred to as the "Opinions").
Analysis on the Construction of Sustainable Development Capacity of Pharmaceutical Enterprises from the Aspect of Investment of R&D Expenses Zhulikou431
December 17, 2021
Recently, semi-annual reports of domestic and foreign pharmaceutical companies have been disclosed one after another. From the data released by major companies, we put aside the highly anticipated...
Investment Potential in Africa’s Pharmaceutical Market Shem Oirere
July 21, 2020
The Covid-19 pandemic outbreak has increased Africa’s disease burden on one hand while opening up possible trade opportunities for global drug originators...
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma PRNewswire
December 19, 2024
PeproMene Bio, Inc.has announced an $11M investment from the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical development of PMB-CT01 (BAFF-R CAR T cell therapy) in patients with relapsed or refractory (r/r) follicular lymphoma.
CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion PR Newswire
December 12, 2024
R-Bridge Healthcare Fund ("R-Bridge") today announced the closing of a non-dilutive growth financing facility of up to US$50 million for Human Investments Ltd.
4D Lifetec Secures CHF 23.3 Mio in a Share and Investment Deal with Xlife Sciences Opening New Horizons in Using AI and Digital Health in Early Cancer Detection B3C newswire
November 06, 2023
In a significant financial milestone, Xlife Sciences AG invests CHF 23.3 million in 4D Lifetec AG, acquiring a 20% stake in the company.
Interpharma Investments Limited Appoints Alfonso "Chito" Zulueta As Non-Executive Chairman PharmaSources
May 06, 2023
Interpharma Investments Limited, holding company of leading healthcare services provider Zuellig Pharma, today announced the appointment of Mr. Alfonso “Chito” Zulueta as Non-Executive Chairman of its Board.
IGIS Asia Investment Management Partners with CHA Bio Group to Launch Life Science Real Estate Platform JV PharmaSources
February 16, 2023
IGIS Asia Investment Management announced this month a partnership with CHA Bio Group, to form a new Asia-Pacific life science real estate investment platform.